Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Lu AA24530 for the treatment of mood and anxiety disorders enters into clinical phase II

26 Oct 2007 - H. Lundbeck A/S and Takeda Pharmaceutical Company Limited announced the decision to investigate Lu AA24530 for the treatment of depression in patients. Based on positive, pre-clinical results, as well as the positive conclusion of the phase I trials in healthy individuals, the first patient in a 600 patient phase II study has been enrolled.
 
Lu AA24530, discovered by Lundbeck, belongs to a new chemical class and represents an approach that is different to currently marketed antidepressants. Lu AA24530 is being jointly developed by Lundbeck and Takeda and is the second most advanced compound in the collaboration on a new class of compounds to treat mood and anxiety disorders. In September 2007, Lundbeck and Takeda formed an alliance to develop and commercialize a portfolio of novel compounds in the US and Japan for the treatment of mood and anxiety disorders, including Lu AA24530 and Lu AA21004, which is in a more advanced clinical development stage.